8 October 2014Genetics

Myriad and Ambry face off at appeals court

A US appeals court has heard oral arguments in a case between Myriad Genetics and a generics company it wants to prevent from marketing its own test for BRCA gene mutations that can lead to breast cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Charpentier CRISPR patent gets good news from Japan

14 December 2023 Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021.

Genetics

Will de-extinct animals be patent eligible in the US?

5 January 2023 Science fiction is becoming science fact but the Alice/Mayo framework throws up some interesting challenges to bringing life back from the dead, explains Brian Hausman of Baker Botts.

Genetics

Gene-editing bill: encouraging innovation or adding complexity?

26 May 2022 UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.

More features

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Myriad and Ambry face off at appeals court

More on this story

Editor's picks

Editor's picks

More features